Effect of diet-induced plasma ceramide on human in vivo microvascular endothelial function.

Am J Physiol Heart Circ PhysiolOct 13, 2026 (epub)
Clinical ResearchCardiology

Tijana Simovic, Maria J Jaramillo-Torres, William J Butak et al.

✦ AI-curated · Sources linked

In 30 seconds

This double-blind, randomized crossover trial examined whether a meal-induced rise in plasma ceramides impairs in vivo microvascular function in 23 healthy young adults. Participants consumed meals rich in long-chain or medium-chain fatty acids, with measurements at baseline and 2 and 4 hours. The long-chain meal increased circulating ceramides in female participants only (P < 0.001), but nitric oxide-dependent and maximal dilation declined similarly after both meals, without sex differences. Microvascular density and perfusion did not change. The findings suggest that an acute ceramide increase was not sufficient to explain the post-meal reduction in microvascular function.

Key findings

  • The long-chain fatty acid-rich meal increased circulating ceramides in female participants only (P < 0.001).
  • Nitric oxide-dependent and maximal dilation were similarly reduced after both meals, with no observed sex differences.
  • Neither meal changed microvascular density or perfusion.

Why it matters

The results distinguish an acute postprandial reduction in microvascular function from a simple effect of circulating ceramide: function declined after both meals, although ceramide elevations occurred only after the long-chain meal. This cautions against attributing short-term vascular responses to ceramide changes alone and highlights the need to understand whether repeated ceramide elevations have different effects.

What to keep in mind

The trial assessed acute responses in a small group of healthy young adults; it does not establish the effects of repeated ceramide elevations or longer-term cardiovascular outcomes.

Source

Published in Am J Physiol Heart Circ Physiol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.